Catalyst Dossier · compiled by CeliA 🧫

Alcon Research (ALC)

Ophthalmic Goods · market cap $11.6B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alcon Inc. (ALC) is a Swiss-American ophthalmic-focused pharmaceutical and medical device company headquartered in Geneva with primary operations in Fort Worth, Texas. The company carries a broad pipeline spanning glaucoma, allergic conjunctivitis, uveitis, AMD, dry eye, and surgical/cataract indications across Phase 2 and Phase 3 stages. With a $11.6B market cap and shares at ~$67.93, the stock trades at a modest discount to the consensus analyst mean target of ~$87.92.

The catalyst path

2026-08-10Earningsimp 5/10
2027-05-15 (est.)Phase 2 · AR-14034 SR implant lower doseimp 7/10

Pipeline

Asset	Phase	Indication
Travoprost Vehicle	Phase 2	Open-angle Glaucoma (OAG)
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%	Phase 3	Allergic Conjunctivitis
LME636 60 mg/mL ophthalmic solution	Phase 2	Acute Anterior Uveitis
Anecortave acetate 30 mg	Phase 2	AMD
AL-3789 Sterile Suspension	Phase 2	Open-angle Glaucoma
AL-4943A ophthalmic solution	Phase 3	Allergic Conjunctivitis
Ofloxacin otic solution	Phase 3	Acute Otitis Media
Difluprednate 0.05% ophthalmic emulsion	Phase 3	Endogenous Anterior Uveitis
Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution	Phase 3	Glaucoma, Open-angle
Brinzolamide 1% ophthalmic suspension	Phase 3	Open-Angle Glaucoma
Difluprednate ophthalmic emulsion, 0.05%	Phase 3	Cataracts
Travoprost 0.004%/Timolol 0.5%	Phase 3	Open-angle Glaucoma
Travoprost 0.004% with and without BAK	Phase 3	Open-angle Glaucoma
Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension	Phase 3	Cataract
Travoprost, Investigational	Phase 3	Open-angle Glaucoma
Next Generation Ophthalmic Irrigating Solution (NGOIS)	Phase 3	Cataract
Tobramycin 0.3%/Dexamethasone 0.05%	Phase 3	Ocular Inflammation Associated With Blepharaconjunctivitis
AL-39324 ophthalmic suspension	Phase 2	Age Related Macular Degeneration
Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension	Phase 3	Open-Angle Glaucoma
Brinzolamide ophthalmic suspension, 1%	Phase 3	Open-Angle Glaucoma

Price & technical context

3-month

-7.7%

6-month

-12.2%

12-month

-21.7%

52-wk range

$62.02–$92.22

vs 50-day MA

+2.8%

vs 200-day MA

-7.8%

Realized vol

29.6%

Max drawdown

-38.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.